# Characteristics and Determinants of Pulmonary Long COVID

- 3
- 4 Michael John Patton<sup>1,2†</sup>, Donald Benson<sup>4</sup>, Sarah W. Robison<sup>3</sup>, Raval Dhaval<sup>3</sup>, Morgan L.
- 5 Locy<sup>3</sup>, Kinner Patel<sup>3</sup>, Scott Grumley<sup>4</sup>, Emily B. Levitan<sup>5</sup>, Peter Morris<sup>3</sup>, Matthew Might<sup>2</sup>,
- 6 Amit Gaggar<sup>3,6‡\*</sup>, and Nathaniel Erdmann<sup>7‡</sup>
- 7
- <sup>1</sup>Medical Scientist Training Program, Heersink School of Medicine, University of
- 9 Alabama at Birmingham, Birmingham, AL, USA
- <sup>2</sup>Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham,
- 11 Birmingham, AL, USA
- <sup>3</sup>Department of Medicine, Pulmonary, Allergy, & Critical Care Medicine Division,
- 13 University of Alabama at Birmingham, AL, USA
- <sup>4</sup>Department of Radiology, University of Alabama at Birmingham, AL, USA
- <sup>5</sup>Department of Epidemiology, University of Alabama at Birmingham, AL, USA
- <sup>6</sup>Birmingham VA Medical Center, Pulmonary Section, Birmingham, AL, USA
- <sup>17</sup> <sup>7</sup>Department of Medicine, Division of Infectious Diseases, University of Alabama at
- 18 Birmingham, AL, USA
- 19 † First Author
- 20 ‡ Co-senior Authors
- 21 \* Corresponding Author
- 22
- 23 Michael John Patton, BA, MD, PhD candidate, mjpatton@uab.edu
- 24 Donald Benson, MD, PhD, donaldbenson@uabmc.edu
- 25 Sarah W. Robison, MD, srobison@uabmc.edu
- 26 Raval Dhaval, MD, draval@uabmc.edu
- 27 Morgan L. Locy, MD, PhD, mllocy@uabmc.edu
- 28 Kinner Patel, MD, kinnerpatel@uabmc.edu
- 29 Scott Grumley, MD, sgrumley@uabmc.edu
- 30 Emily B. Levitan, ScD, emilylevitan@uabmc.edu
- 31 Peter Morris, MD, pmorris@uabmc.edu
- 32 Matthew Might, PhD, might@uab.edu
- 33 Amit Gaggar\*, MD, PhD, Email: agaggar@uabmc.edu, Address: Bevill Research
- Building, 845 19<sup>th</sup> Street South, Birmingham, AL, 35294, Phone: 205-934-4304
- 35 Nathaniel Erdmann, MD, PhD, nberdmann@uabmc.edu
- 36
- 37
- 38 Word Count: 4777 (Abstract, Introduction, Results, Discussion, References, Legends)
- 39

# 40 STRUCTURED ABSTRACT

#### 41 RATIONALE

42 Persistent cough and dyspnea are prominent features of post-acute sequelae of SARS43 CoV-2 (termed 'Long COVID'); however, physiologic measures and clinical features
44 associated with these pulmonary symptoms remain poorly defined.

#### 45 **OBJECTIVES**

46 Using longitudinal pulmonary function testing (PFTs) and CT imaging, this study aimed

47 to identify the characteristics and determinants of pulmonary Long COVID.

#### 48 METHODS

49 The University of Alabama at Birmingham Pulmonary Long COVID cohort was utilized to 50 characterize lung defects in patients with persistent pulmonary symptoms after 51 resolution primary COVID infection. Longitudinal PFTs including total lung capacity (TLC) 52 and diffusion limitation of carbon monoxide (DLCO) were used to evaluate restriction 53 and diffusion impairment over time in this cohort. Analysis of chest CT imaging was used to phenotype the pulmonary Long COVID pathology. Risk factors linked to 54 55 development of pulmonary Long COVID were estimated using univariate and multivariate logistic regression models. 56

#### 57 MEASUREMENTS AND MAIN RESULTS

Longitudinal evaluation 929 patients with post-COVID pulmonary symptoms revealed diffusion impairment (DLCO  $\leq$ 80%) and restriction (TLC  $\leq$ 80%) in 51% of the cohort (n=479). In multivariable logistic regression analysis (adjusted odds ratio; aOR, 95%)

61 confidence interval [CI]), invasive mechanical ventilation during primary infection 62 conferred the greatest increased odds of developing pulmonary Long COVID with 63 diffusion impaired restriction (aOR=10.9 [4.09-28.6]). Finally, a sub-analysis of CT 64 imaging identified evidence of fibrosis in this population.

#### 65 CONCLUSIONS

Persistent diffusion impaired restriction was identified as a key feature of pulmonary
Long COVID. Subsequent clinical trials should leverage combined symptomatic and
quantitative PFT measurements for more targeted enrollment of pulmonary Long COVID
patients.

- ~ ~

# 84 INTRODUCTION

A major consequence of the COVID-19 pandemic has been the complex and 85 frequently debilitating post-acute sequelae of SARS-CoV-2 infection (PASC, also termed 86 87 'Long COVID'), estimated to occur in 10% of patients after primary infection.<sup>1,2</sup> To date, over 150 distinct Long COVID symptoms involving every major organ system have been 88 reported.<sup>3</sup> Recent efforts to develop a consensus definition for Long COVID using 89 symptom clustering have highlighted broad disease sub-types associated with chronic 90 fatigue, post-exertional malaise, brain fog, and loss of smell or taste.<sup>4</sup> These efforts 91 92 represent an important first step for Long COVID research; however, characterizing discreet endotypes with widely available quantitative physiologic measurements is 93 94 essential for standardizing Long COVID diagnosis and management.

95 Prolonged pulmonary symptoms, notably dyspnea and cough, are among the most 96 commonly reported manifestations of Long COVID (hereon referred to as 'pulmonary 97 Long COVID').<sup>4-6</sup> Although pulmonary symptoms are frequently reported, the underlying 98 cause(s) and clinical trajectory of Long COVID patients suffering from these symptoms 99 remains unclear. Prior studies have suggested diffusion impairment that resolves within 1-year of hospitalization is a common feature of post-acute COVID-19.7-10 Other post-100 101 acute COVID follow-up studies have reported radiologic evidence of lung pathology characterized by ground glass opacities and fibrotic changes.<sup>11–18</sup> These results have 102 103 provided valuable insight into post-COVID lung pathology, but are limited by small cohort 104 size and inherently biased towards post-acute COVID patients, rather than Long COVID 105 populations presenting for persistent pulmonary complaints.

106	To address this knowledge gap, we leveraged a large, demographically diverse
107	cohort exclusively comprised of Long COVID patients experiencing pulmonary
108	symptoms persisting for ≥1 month after resolution of acute SARS-CoV-2 infection. Using
109	longitudinal pulmonary function testing (PFT) and computerized tomography (CT)
110	imaging, we identify specific disease features and risk factors linked to the development
111	of pulmonary Long COVID. These presentations capture the population of patients with
112	persistent clinical symptoms and reflect the natural history of pulmonary Long COVID.
113	Lastly, we provide evidence for a novel endotype of Long COVID defined by persistent
114	diffusion impairment and pulmonary restriction.
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	

## 130 METHODS

#### 131 Study Design and Population

132 This single-center, retrospective cohort study was performed among adult patients (≥18 years) with a positive COVID-19 PCR and/or rapid antigen test during the study window 133 134 (03/2020-08/2023), followed by self- or physician referral to the University of Alabama at 135 Birmingham (UAB) Post-COVID Pulmonary Clinic for complaint of unresolved respiratory 136 symptoms. Pulmonary Long COVID was defined as pulmonary symptoms persisting for 137 ≥1 month that had developed ≥28 days after resolution of primary SARS-CoV-2 138 infection. Baseline (1st visit) PFTs and CT scans were defined by the first date of the 139 measurement within a window of 14-days prior to and 6-months after the patient's 1st 140 Long COVID clinic visit date. Follow-up measurements (termed 2nd and 3rd visit) were 141 restricted to the study window and had to occur after the first encounter measurement. 142 The cohort was stratified by percent predicted diffusion capacity for carbon monoxide 143 (DLCO; normal=DLCO >80%, impaired=DLCO ≤80%) and percent predicted total lung 144 capacity (TLC) in accord with the American Thoracic Society consensus definition for 145 restrictive lung disease. Lung restriction sub-groupings were (1) no restriction TLC 146 >80%, (2) mild restriction TLC 71-80%, (3) moderate restriction TLC 51-70%, (4) severe 147 restriction TLC ≤50%.<sup>19,20</sup> All pulmonary function studies were conducted utilizing the same equipment (Vyntus<sup>™</sup> system from Vyaire Medical Incorporated). 148

149

150

151

# Patient Variables Extracted from Electronic Medical Record and Radiographic Images

Clinical variables were extracted for all patients in the cohort including: advanced age 155 156 (≥65 years), biological sex, elevated BMI (≥30), smoking history (never, former, or current smoker), pre-COVID vaccination status, ICU admission, COVID-19 severity 157 158 (assessed using the WHO score system representing maximum oxygen therapy support 159 required), and therapeutics (dexamethasone, remdesivir, days on a specific oxygen support device) during primary infection, SARS-CoV-2 variant, and months from primary 160 infection to first Long COVID clinic visit.<sup>21</sup> Pre-COVID comorbidities (renal, pulmonary, 161 162 failure hypertension. diabetes. obstructive heart or sleep apnea. and 163 immunosuppression) were determined by physician review of medical records. Chest 164 CT imaging was assessed by two blinded cardiothoracic radiologists for the presence or 165 absence of 6 pulmonary imaging findings: lung consolidation, ground-glass opacities, 166 reticulations. other fibrotic-like changes (i.e. architectural distortion. traction bronchiectasis and honeycombing; termed 'other fibrosis'), 167 bronchiectasis, and 168 emphysema (see eTable 3 for two-reader similarity evaluation). An overall severity score 169 was determined using a previously defined image CT scoring system quantifying 170 abnormalities in all 5 lung lobes with scores ranging from 0 (no involvement) to 25 (multi-lobe involvement).<sup>22</sup> Detailed information on variables extracted can be found in 171 the supplemental materials (eTable 1). 172

173

## 176 Statistical Analysis

Cohort statistics were reported with mean ±standard deviation or median [Q1-Q3] in Table 1. Alluvial diagrams were used to assess relative DLCO and TLC improvement or decline in patients with 3-consecutive follow-ups visits (Figure 2C). Logistic regression models (unadjusted variable and multi-variable adjusted) were used to discover risk factors for developing diffusion impairment (DLCO≤80%) with severe or moderate restriction (TLC≤70%) at 1st Long COVID clinic visit (Table 2; see eTable 1 for details on model variables and eTables 5-7 for model sensitivity testing omitting patients without a primary COVID infection hospitalization and patients with pre-existing pulmonary comorbities). All modeling results are reported as either unadjusted (OR) or adjusted odds ratios (aOR) with bootstrapped (n=1000 iterations) 95% confidence intervals (CI). All statistical analyses were performed using R (version 4.2, R Foundation).

199

# 200 **RESULTS**

### 201 Study Population

A total of 1,097 patients with prolonged pulmonary symptoms after primary 202 203 SARSCoV-2 infection were identified based upon their evaluation in post-acute COVID 204 pulmonary clinic. After exclusion, 929 patients with prolonged pulmonary symptoms 205 (dyspnea, cough, or chest discomfort) lasting  $\geq 1$  month after resolution of primary 206 SARS-CoV-2 infection and a subsequent PFT were included in this study (Figure 1, Table 1). To evaluate the role of pulmonary abnormalities in DLCO and evidence of pro-207 208 fibrotic processes, we stratified patients by diffusion impairment and severity of 209 pulmonary restriction as measured by first post-acute PFT. Median time from primary 210 SARS-CoV-2 infection to 1st Long COVID clinic visit was 125 days for diffusion impaired 211 patients and 148 days for patients with normal diffusion capacity (Table 1). Patient age 212 (mean,  $\pm$ SD) for the diffusion impaired group was 56 $\pm$ 13 years compared to 48 $\pm$ 14 years 213 in the normal diffusion group (Table 1). For both groups, the majority of primary SARS-214 CoV-2 infections occurred during the alpha-variant wave (range: 62-63%), followed by 21-23% and 15-16% occurring in the delta and omicron waves, respectively (eTable 2). 215 216 Differences in primary pulmonary symptom reported at 1st Long COVID clinic visit were 217 unremarkable between patients with and without diffusion impairment (range; dyspnea: 218 76-79%, cough: 17-19%, chest discomfort: 4%).

We sought to determine how acute disease severity contributed to PFT findings for patients with pulmonary Long COVID. Acute disease severity was stratified by peak WHO ordinal score. Of the 73 patients who required invasive mechanical ventilation

222 (IMV), only 3 were in the normal diffusion capacity group (Table 1). Increased frequency 223 and duration of oxygen support was observed among diffusion impaired patients with the 224 severe restriction group (IMV: 32%, HFNC: 22%) exceeding that of the moderate (IMV: 225 9%, HFNC: 16%), mild (IMV: 6%, HFNC: 14%), and no restriction groups (IMV: 3%, 226 HFNC: 5%; Table 1). A similar trend of increased time of oxygen therapy (median [Q1-227 Q3]) during primary infection was also observed in diffusion impaired patients (IMV: 18 228 [8-35] days; HFNC: 5 [3-8] days, and nasal cannula: 7 [4-11] days; eTable 2). 229 Differences in vaccination, pre-existing pulmonary disease or obstructive sleep apnea, 230 and smoking history prior to primary SARS-CoV-2 infection were minimal between 231 diffusion impaired and normal groups (Table 1). Patients with diffusion impairment had a 232 greater proportion of pre-existing diabetes (21%) and heart failure or hypertension (52%) 233 compared to the normal diffusion group with 14% and 33%, respectively (Table 1). 234 Cumulative lung involvement (25 points total, 5 points per lobe; median [Q1-Q3]) was 235 higher in the diffusion impaired group (9 [1-17]) compared to the normal group (0 [0-2]). 236 The degree of lung involvement on CT imaging for diffusion impaired patients correlated 237 with increasing severity of lung restriction (none: 3 [1-7], mild: 3 [0-9], moderate: 7 [1-13], 238 severe: 17 [9-21]; Table 1). Further characteristics of the cohort are presented in Table 1 239 and eTable 2.

240

241

242

243

244

245

246

247

# 248 Longitudinal Evaluation of Pulmonary Function Testing

To assess physiological differences between patients with pulmonary Long COVID, 249 250 we evaluated longitudinal PFTs over three total Long COVID visits. After 1st visit 251 stratification, patients without diffusion impairment had, on average, normal lung 252 capacity during the visit 2 visits (TLC 1st: 82±15%, 2nd: 79±13%) with mild decline on 253 3rd visit (72±15%) compared to patients with diffusion impairment on respective follow-254 up visits (TLC 1st: 65±18%, 2nd: 65±15%, 3rd: 64±15%) (Figure 2A, eTable 4). Diffusion impaired patients with severe or moderate restriction experienced little to no 255 256 improvement in TLC at 2nd (severe:  $51\pm14\%$ , moderate:  $66\pm11\%$ ) or 3rd visit (severe: 257 55±14%, moderate: 65±12%) (Figure 2A, eTable 4). Overall, patients with normal 258 diffusion capacity at 1st visit maintained normal or above normal DLCO at the follow-up 259 visits (DLCO 1st: 95±12%, 2nd: 93±16%, 3rd: 90±15%), regardless of the level of 1st 260 visit restriction (Figure 2B, eTable 4). In contrast, patients with diffusion impairment at 1st visit remained, on average, diffusion impaired at all follow-up visits (DLCO 1st: 59±16%, 261 2nd: 66±19%, 3rd: 65±19%), with a clear association between worsening TLC and 262 263 DLCO (Figure 2B, eTable 4). Additional PFT measurements are provided in eTable 4.

Alluvial diagrams were used to assess improvement or decline in diffusion impairment and restriction for patients with 3-consecutive PFTs at the UAB pulmonary Long COVID clinic (N=100, Figure 2C). Overall, we observed that the majority of patients with diffusion impairment and severe or moderate restriction at 1st visit had persistent restriction and diffusion impairment at 2nd and 3rd follow-up visits (Figure 2C). Improvement from diffusion impairment at any level of restriction was rare, with only 5

patients regaining normal TLC and DLCO by their 3rd visit. Over half of the normal diffusion capacity patients (n=11) had some level of lung restriction at 1st visit (n=1 mild, n=9 moderate, n=1 severe). Restriction or diffusion impaired restriction were the predominant phenotypes observed by the 3rd follow-up visit, thereby indicating an earlier stage of disease followed by progression among the normal diffusion capacity patients (Figure 2C).

#### **Risk Factors for Developing Pulmonary Long COVID with Severe**

277

# Pulmonary Restriction

278 Logistic regression models were used to identify risk factors for developing Long 279 COVID with combined diffusion impairment (DLCO ≤80%) and severe or moderate 280 restriction (TLC  $\leq$ 70%). Unadjusted univariable modeling revealed advanced age  $\geq$ 65 281 years (OR=1.63 [1.23-2.23]), male sex (OR=1.88 [1.43-2.48]), renal disease (OR=2.48 [1.474.15]), diabetes (OR=1.82 [1.30-2.51]), heart failure or hypertension (OR=2.54 282 [1.98-3.32]), smoking history (OR=1.39 [1.03-1.86]), ICU admission (OR=6.15 [4.24-283 284 9.36]), and use of nasal cannula (OR=4.21 [2.90-6.07]), high-flow nasal cannula (OR=6.10 [3.92-9.82]), and invasive mechanical ventilation (OR=16.0 [8.87-34.4]) as 285 independent risk factors for developing pulmonary Long COVID with severe or moderate 286 287 restriction (Table 2). After adjusting for all variables, we observed that invasive 288 mechanical ventilation conferred the greatest increased odds of developing pulmonary 289 Long COVID with diffusion impairment and severe or moderate restriction (aOR=10.9 [4.09-28.6]), followed by nasal cannula (aOR=4.0 [2.61-6.33]) and high-flow nasal 290 291 cannula (aOR=3.86 [1.73-8.09]) use during primary SARS-CoV-2 infection, heart failure 292 or hypertension (aOR=2.09 [1.46-2.99]) and male sex (aOR=1.44 [1.03-1.98]; Table 2; 293 reference group: un-hospitalized primary infection patients). In a sub-analysis using only 294 hospitalized patients (WHO score 4-7), the association of invasive mechanical ventilation 295 with diffusion impairment and severe or moderate restriction was comparable with whole 296 cohort results (aOR=9.56 [3.22-32.6] vs. reference group of hospitalized room-air 297 patients: eTable 5). To evaluate the potential effect of patients with pre-existing pulmonary comorbidities on our model results, further sensitivity testing was performed 298 299 Overall, the results show that invasive mechanical ventilation still (eTables 6-7). 300 conferred the greatest risk for development of pulmonary Long COVID with diffusion 301 impairment and severe or moderate restriction (eTable 6, cohort sans patients with 302 pulmonary comorbidities vs. reference group of non-hospitalized patients aOR=14.5 303 [5.0-50.9]; eTable 7 cohort sans patients pulmonary comorbidities vs. reference group of 304 hospitalized room-air patients aOR=15.2 [4.72-68.1]).

305

# **Assessment of CT Imaging and Pathology**

307 CT imaging was performed on a total of 308 patients (33%; n=246 diffusion 308 impaired sub-group, n=62 diffusion normal sub-group; Table 1). CT pathology and 309 increased lung involvement were predominantly found in diffusion impaired patients with 310 severe or moderate restriction. CT scoring of images taken within 6-months of the 1st 311 Long COVID visit identified ground glass opacities (85%), reticulations (82%), 312 bronchiectasis (69%), and fibrotic changes (65%) as the defining pathologies in the 313 majority of diffusion impaired severe restriction patients (Figure 3A, eTable 2). A similar 314 pathologic profile was found in diffusion impaired patients with moderate restriction

315	(Figure 3B). Univariable and multivariable logistic regression modeling was performed to
316	determine if CT pathologies were associated with increased odds of developing
317	pulmonary Long COVID with severe or moderate restriction (eTable 8). The significant
318	unadjusted odds ratios for developing severe restriction were associated with ground
319	glass opacities (OR=4.11 [2.50-6.96]), reticulations (OR=5.49 [3.24-9.35]), fibrotic
320	changes (OR=5.27 [3.10-9.60]), bronchiectasis (OR=5.27 [3.10-9.60]), and consolidation
321	(OR=2.35 [1.02-9.06]); however, only reticulations (aOR=2.12 [1.01-4.34]) maintained a
322	significance in multivariable modeling (eTable 8).
323	
324	
325	
326	
327	
328	
329	
330	
331	
332	
333	
334	
335	
336	
337	

# 342 **DISCUSSION**

343 Our current understanding of persistent pulmonary defects from SARS-CoV-2 infection are primarily derived from prospective follow-up studies assessing patient 344 outcomes after hospitalization with acute COVID-19. Gradual recovery of impaired 345 346 diffusion capacity (DLCO ≤80%) and radiographic evidence of fibrotic pulmonary tissue are among the most commonly reported observations.<sup>7–10,23–27</sup> Although these studies 347 348 offer key insights into the trajectory of acute COVID recovery, characterizing patients 349 without post-COVID symptoms limit the applicability of these findings to Long COVID patients with persistent dyspnea, cough, and chest discomfort. To address this 350 351 knowledge gap, we leveraged a large, demographically diverse cohort comprised exclusively of Long COVID patients with persistent pulmonary symptoms. For this 352 353 cohort, we aligned robust medical record data requiring no imputation, quantitative CT 354 imaging, and longitudinal pulmonary function testing (PFT) to identify the characteristics 355 and determinants of pulmonary Long COVID. Our study establishes a clear association 356 between burden of acute COVID disease and the development of persistent lung 357 restriction with diffusion impairment. Collectively, these results comprehensively define 358 pathology for Long COVID that can be readily measured with PFTs and provides 359 opportunity to better study the post-viral interplay of pulmonary symptoms with 360 alterations in lung physiology.

Demographic risk factors (aOR [95% CI]) associated with the development of pulmonary Long COVID with diffusion impairment and severe or moderate restriction included male sex (aOR=1.44 [1.05-2.00]) and pre-existing heart failure and hypertension (aOR=2.07 [1.46-3.02]; Table 2, eTable 5). These findings differ from a

365 recent meta-analysis of multi-organ Long COVID symptoms that noted an elevated risk in females (aOR=1.56) and individuals over 40 years of age (aOR=1.21).<sup>28</sup> Our findings 366 367 emphasize differences between the assessments obtained from broad symptom 368 observations and physiological readouts in pinpointing at-risk populations. In Long 369 COVID patients complaining of prolonged pulmonary symptoms, prior studies have 370 suggested that dyspnea is a major feature and that symptoms can persist for months after initial infection.<sup>9,29</sup> Our study affirmed this observation with 78% (n=725) of the UAB 371 372 pulmonary Long COVID cohort identifying dyspnea as the primary symptom, followed by 373 18% (n=167) with cough and 4% (n=37) with chest discomfort (Table 1). Notably, the 374 complaint of dyspnea remained consistent (>70%) across all degrees of diffusion impairment, restriction, and levels of lung involvement seen on CT imaging (Table 1, 375 376 eTable 2). This suggests symptoms alone do not provide sufficient granularity to identify distinct endotypes of pulmonary Long COVID, thereby highlighting the importance of 377 378 incorporating routine PFTs in the diagnostic evaluation of this patient population.

379 Our study demonstrates that the severity of hypoxia during primary SARS-CoV-2 380 infection is a critical factor in the development of pulmonary Long COVID with persistent 381 diffusion impairment and restriction (Table 2). Notably, the post-hospitalization PFT impairments in pulmonary Long COVID contrast with previously described post ARDS 382 383 findings in non-COVID patients, where subjects predominately present with isolated 384 diffusion impairment which improves to normal levels over a 6 month-1 year period and limited lung restriction at any time-point.<sup>30–33</sup> In addition to marked differences in lung 385 386 physiology, the presence of reticulations, bronchiectasis, ground glass opacities, and 387 fibrotic changes in pulmonary Long COVID CT images are distinct from ARDS which has been predominantly described by the presence of ground glass opacities and 388

reticulations.<sup>32</sup> Cumulatively, our physiologic and radiographic evidence suggest that pulmonary Long COVID is a pro-fibrotic disease process that is distinct from ARDS; however, future studies are warranted and needed to further elucidate the differences.

392 The biologic mechanisms underlying these symptomatic, physiologic, and 393 radiographic changes are poorly understood, but there is increasing evidence that pro-394 fibrotic interstitial lung changes are occurring in dyspneic patients as early as 1 month post-COVID infection.<sup>18,34–36</sup> From a molecular perspective, several independent lines of 395 396 evidence have shown that altered immune function, dysregulation of systemic 397 neutrophilic signatures, and persistent inflammation and presence of viral antigens are associated with Long COVID.37-40 While few studies have been conducted in the Long 398 COVID lung, a prior spatial transcriptomic lung autopsy study from COVID-19 acute lung 399 400 injury demonstrates a distinct fibro-proliferative phenotype relative to influenza infection.<sup>41</sup> If true, pulmonary fibrosis therapeutics like Nintedanib and Pirfenidone, which 401 402 have been sparingly used in post-COVID associated fibrosis, may be uniquely suited for the subset of pulmonary Long COVID patients with diffusion impaired restriction.<sup>42,43,46</sup> 403 This report provides novel definition of a distinct endotype of Long COVID and 404 405 emphasizes the need to stratify patients for targeted therapeutic and clinical 406 management.

This study has limitations. Due to the retrospective nature of the cohort, PFTs were not taken before or during primary SARS-CoV-2 infection, and therefore could not be compared to measurements taken at the first Long COVID clinic visit. While this large, demographically diverse cohort offers a unique opportunity to characterize pulmonary presentations of Long COVID, patients presented to the Long COVID clinic at different time intervals after primary COVID infection, and follow-ups were limited to attended

visits. Similarly, inherent bias towards more severe disease is present in patients who
had CT imaging performed. Despite these limitations, the combination of an objective
physiologic metric in longitudinal PFTs and a previously established Long COVID
symptomatic signature provide an important foundation for future Long COVID studies.

Although dyspnea is present in a majority of pulmonary Long COVID patients, reported symptoms were not representative of the degree of diffusion impairment and restriction across the cohort.<sup>44</sup> The additional granularity provided with PFTs highlights the utility of a broadly available clinical test to identify pulmonary endotypes associated with persistent physiologic impairment. These insights underscore the need for medical providers to incorporate PFT measurements as a routine step for evaluating Long COVID patients with pulmonary complaints. Informed stratification of patients experiencing pulmonary Long COVID is critical as this population is likely to require high utilization of health care services and would likely benefit from early therapeutic interventions.45 

# 440 **ACKNOWLEDGEMENTS**

#### 441 **AUTHOR CONTRIBUTIONS**

Michael John Patton (MJP), Nathaniel Erdmann (NE), Donald Benson (DB), Scott 442 443 Grumbley (SG), Emily B. Levitan (EBL), Amit Gaggar (AG), Sarah W. Robison (SWR), 444 Raval Dhaval (RD), Kinner Patel (KP), Morgan L. Locy (MLL), Peter Morris (PM), and Matthew Might (MM) co-conceived the project, prepared the main text, and oversaw the 445 446 UAB cohort creation. MJP processed and analyzed EMR data to create all tables and 447 figures in the main text and supplement of this manuscript. DB analyzed and scored CT 448 images. SG analyzed and scored a subset of CT images. We thank Dr. Jeanne 449 Marrazzo, Dr. Surya Bhatt, and Dr. Mark Dransfield for contributing critical comments 450 and additions to the main text and supplement. NE oversaw IRB approval from the 451 University of Alabama at Birmingham (UAB IRBs: 300006291, 300006205). NE, MM, 452 RD, and AG, obtained funding and supervised the overall study. All co-authors reviewed 453 and approved the final version of the manuscript.

454

#### 455 **FUNDING & DISCLOSURES**

456 This work was supported by the National Institute of Allergy and Infectious Diseases

(AI156898, K08AI129705), the National Heart, Lung, and Blood Institute (HL153113,
OTA21-015E, HL149944), and the COVID-19 Urgent Research Response Fund
established by the Hugh Kaul Precision Medicine Network at the University of Alabama
at Birmingham. No co-authors have any disclosures.

461

462

# 463 **REFERENCES**

- 464 1. Ballering, A. V., van Zon, S. K. R., Olde Hartman, T. C., Rosmalen, J. G. M. &
- 465 Initiative, L. C. R. Persistence of somatic symptoms after COVID-19 in the
- 466 Netherlands: an observational cohort study. The Lancet 2022; 400, 452–461.
- 467 doi:10.1016/S0140-6736(22)01214-4
- 468 2. Bull-Otterson, L. et al. Post–COVID Conditions Among Adult COVID-19 Survivors
- Aged 18–64 and 65 Years —United States, March 2020–November 2021. MMWR.
- 470 Morbidity and Mortality Weekly Report 71 2022. doi:10.15585/mmwr.mm7121e1
- 3. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
- 472 mechanisms and recommendations. Nature Reviews Microbiology 2023; 21, 133–
- 473 146. doi:10.1038/s41579-022-00846-2
- 474 4. Thaweethai, T. et al. Development of a Definition of Postacute Sequelae of SARS-
- 475 CoV-2 Infection. The Journal of the American Medical Association 2023; 329, 1934–
- 476 1946. doi:10.1001/jama.2023.8823
- 477 5. Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months
- of symptoms and their impact. EClinicalMedicine 2021; 38, 101019.
- 479 doi:10.1016/j.eclinm.2021.101019
- 480 6. Subramanian, A. et al. Symptoms and risk factors for long COVID in non-
- 481 hospitalized adults. Nature Medicine 2022; 28, 1706–1714. doi:10.1038/s41591482 022-01909-w
- 483 7. Wu, X. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in
  484 patients following COVID-19-related hospitalisation: a prospective study. The

485 Lancet Respiratory Medicine 2021; 9, 747–754. doi:10.1016/S2213-

- 486 2600(21)00174-0
- 487 8. Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from
- 488 hospital: a cohort study. The Lancet 2021; 397, 220–232. doi:10.1016/S0140-
- 489 6736(20)32656-8

4

- Huang, L. et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal
  cohort study. The Lancet 2021; 398, 747–758. doi:10.1016/S0140-6736(21)01755-
- 492
- Evans, R. A. et al. Physical, cognitive, and mental health impacts of COVID-19 after
  hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study The
  Lancet Respiratory Medicine 2021; 11, 1275-1287. doi:10.1016/S2213-
- 496 2600(21)00383-0
- 497 11. Stewart, I. et al. Residual Lung Abnormalities after COVID-19 Hospitalization:
- 498 Interim Analysis of the UKILD Post-COVID-19 Study. American Journal of
- 499 Respiratory and Critical Care Medicine 2023; 207, 693–703.
- 500 doi:10.1164/rccm.202203-0564OC

501 12. Yu, J. Z. et al. Lung perfusion disturbances in nonhospitalized post-COVID with

- 502 dyspnea-A magnetic resonance imaging feasibility study. Journal of Internal
- 503 Medicine 2022; 292, 941–956. doi:10.1111/joim.13558
- 13. Watanabe, A. et al. One-year follow-up CT findings in COVID-19 patients: A
- 505 systematic review and meta-analysis. Respirology 2022; 27, 605–616.
- 506 doi:10.1111/resp.14311
- 507 14. Baillie, J. K. et al. Multiorgan MRI findings after hospitalisation with COVID-19 in the

508		UK (C-MORE): a prospective, multicentre, observational cohort study. The Lancet
509		Respiratory Medicine 2023; 11:1003-1019. doi:10.1016/S2213-2600(23)00262-X
510	15.	So, M., Kabata, H., Fukunaga, K., Takagi, H. & Kuno, T. Radiological and functional
511		lung sequelae of COVID-19: a systematic review and meta-analysis. BMC
512		Pulmonary Medicine 2021; 21, 97. doi:10.1186/s12890-021-01463-0
513	16.	Mandal, S. et al. 'Long-COVID': a cross-sectional study of persisting symptoms,
514		biomarker and imaging abnormalities following hospitalisation for COVID-19.
515		Thorax 2021; 76, 396–398. doi:10.1136/thoraxjnl-2020-215818
516	17.	Liu, C. et al. Chest Computed Tomography and Clinical Follow-Up of Discharged
517		Patients with COVID-19 in Wenzhou City, Zhejiang, China. Annals of the American
518		Thoracic Society 202; 17, 1231–1237. doi:10.1513/AnnalsATS.202004-324OC
519	18.	Mylvaganam, R. J., Bailey, J. I., Sznajder, J. I., Sala, M. A. & Consortium, N. C. C.
520		C. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.
521		European respiratory review : an official journal of the European Respiratory
522		Society 2021; 30. doi:10.1183/16000617.0194-2021
523	19.	Pellegrino, R et al. Interpretative strategies for lung function tests. The European
524		Respiratory Journal 2005; 26, 948–968. doi:10.1183/09031936.05.00035205
525	20.	Stanojevic, S. et al. ERS/ATS technical standard on interpretive strategies for
526		routine lung function tests. The European Respiratory Journal 2022; 60.
527		doi:10.1183/13993003.01499-2021

- 528 21. Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 Final Report. The
- 529 New England Journal of Medicine 2020; 383, 1813–1826.
- 530 doi:10.1056/NEJMoa2007764
- 531 22. Pan, F. et al. Time Course of Lung Changes at Chest CT during Recovery from
- 532 Coronavirus Disease 2019 (COVID-19). Radiology 2020; 295, 715–721.
- 533 doi:10.1148/radiol.2020200370
- 534 23. Nirmal, A. S. et al. Delayed lung function testing after COVID-19 to detect persistent
- 535 lung function abnormalities The DELTA COVID-19 lung function study. Journal of
- family medicine and primary care 2022; 11, 7351–7356.
- 537 doi:10.4103/jfmpc.jfmpc\_703\_22
- 538 24. Stockley, J. A. et al. Lung function and breathing patterns in hospitalised COVID-19
- 539 survivors: a review of post-COVID-19 Clinics. Respiratory Research 2021; 22, 255.
- 540 doi:10.1186/s12931-021-01834-5
- 541 25. Salem, A. M. et al. The Long-Term Impact of COVID-19 Pneumonia on the
- 542 Pulmonary Function of Survivors. International journal of general medicine 2021;
- 543 14, 3271–3280. doi:10.2147/IJGM.S319436
- 544 26. Stylemans, D. et al. Evolution of lung function and chest CT 6 months after COVID-
- 545 19 pneumonia: Real-life data from a Belgian University Hospital. Respiratory
- 546 Medicine 2021; 182, 106421. doi:10.1016/j.rmed.2021.106421
- 547 27. González, J. et al. Pulmonary Function and Radiologic Features in Survivors of
- 548 Critical COVID-19: A 3-Month Prospective Cohort. Chest 2021; 160, 187–198.

#### 549 doi:10.1016/j.chest.2021.02.062

330 ZU. Isampasian, v. et al. Nisk i actuis Associated with i Ust-COVID-13 Condition	550	28.	Tsampasian.	V. et al. Risk Factors Associated With Post-COVID-19 Condition:
--	-----	-----	-------------	---

- 551 Systematic Review and Meta-analysis. JAMA internal medicine 2023; 183, 566–
- 552 580. doi:10.1001/jamainternmed.2023.0750
- 553 29. Cares-Marambio, K. et al. Prevalence of potential respiratory symptoms in survivors
- of hospital admission after coronavirus disease 2019 (COVID-19): A systematic
- review and meta-analysis. Chronic Respiratory Disease 2021; 18.
- 556 doi:10.1177/14799731211002240
- 30. Herridge, M. S. et al. One-year outcomes in survivors of the acute respiratory
- distress syndrome. The New England Journal of Medicine 2003; 348, 683–693.
- 559 doi:10.1056/NEJMoa022450
- 560 31. Herridge, M. S. et al. Functional disability 5 years after acute respiratory distress
- syndrome. The New England Journal of Medicine 2011; 364, 1293–1304.
- 562 doi:10.1056/NEJMoa1011802
- 32. Masclans, J. R. et al. Quality of life, pulmonary function, and tomographic scan
  abnormalities after ARDS. Chest 2011; 139, 1340–1346. doi:10.1378/chest.10-2438
- 565 33. Lindén, V. B., Lidegran, M. K., Frisén, G, Dahlgren, P, Frenckner, B. P. & Larsen, F.
- 566 ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and
- 567 function and health-related quality of life. Acta Anaesthesiologica Scandinavica
- 568 2009; 53, 489–495. doi:10.1111/j.1399-6576.2008.01808.x

569	34.	Ambardar,	S. F	R., Hightower,	S. L.,	Huprikar,	N. A.,	Chung,	K. K.,	Singhal, A	۸. 8
				,	<u> </u>		,	<u> </u>	,	- · · · · · · · · · · · · · · · · · · ·	

- 570 Collen, J. F. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current
- 571 Pandemic. Journal of clinical medicine 2021; 10. doi:10.3390/jcm10112452
- 572 35. McGroder, C. F. et al. Pulmonary fibrosis 4 months after COVID-19 is associated
- 573 with severity of illness and blood leucocyte telomere length. Thorax 2021; 76,
- 574 1242–1245. doi:10.1136/thoraxjnl-2021-217031
- 575 36. Bazdyrev, E., Rusina, P., Panova, M., Novikov, F., Grishagin, I. & Nebolsin, V. Lung
- 576 Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel,
- 577 Switzerland) 2021; 14. doi:10.3390/ph14080807
- 37. Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. & Boyton, R. J. The
- immunology of long COVID. Nature Reviews Immunology 2023; 23, 618-634.
- 580 doi:10.1038/s41577-023-00904-7
- 581 38. George, P. M. et al. A persistent neutrophil-associated immune signature
- 582 characterizes post-COVID-19 pulmonary sequelae. Science Translational Medicine
- 583 2022; 14(671):eabo5795. doi:10.1126/scitranslmed.abo5795
- 39. Files, J. K. et al. Duration of post-COVID-19 symptoms is associated with sustained
- 585 SARS-CoV-2-specific immune responses. Journal of Clinical Investigation Insight
- 586 2021; 6(15):e151544. doi:10.1172/jci.insight.151544
- 40. Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J. & Ho, A. SARS-CoV-2,
- 588 SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
- infectiousness: a systematic review and meta-analysis. The Lancet Microbe 2021;
- 590 2, e13–e22. doi:10.1016/S2666-5247(20)30172-5

- 41. Margaroli, C. et al. Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies
- 592 differential transcriptional signatures. Cell reports Medicine 2021; 2, 100242.
- 593 doi:10.1016/j.xcrm.2021.100242
- 42. Zhou, X. et al. Case Report: Pirfenidone in the Treatment of Post-COVID-19
- 595 Pulmonary Fibrosis. Frontiers in medicine 2022; 9:925703.
- 596 doi:10.3389/fmed.2022.925703
- 43. Saiphoklang, N., Patanayindee, P. & Ruchiwit, P. The Effect of Nintedanib in Post-
- 598 COVID-19 Lung Fibrosis: An Observational Study. Critical care research and
- 599 practice 2022; 9972846. doi:10.1155/2022/9972846
- 44. Perlis, R. H. et al. Prevalence and correlates of long COVID symptoms among US
- adults. JAMA Network Open 2022; 5, e2238804.
- 602 doi:10.1001/jamanetworkopen.2022.38804
- 45. Cutler, D. M. The costs of long COVID. JAMA Health Forum 2022; 3, e221809.
- 604 doi:10.1001/jamahealthforum.2022.1809
- 46. Sgalla G, Leone PM, Gualano G, Simonetti J, Comes A, Verdirosi D, Di Gennaro F,
- Larici AR, Ianniello S, Cicchetti G, Fusco N, Pani M, Palmieri F, Richeldi L. A
- randomized trial of pamrevlumab in patients with COVID -19
- 608 pneumonia. Respirology 2023; doi:10.1111/resp.14575.
- 609
- 610
- 611
- 612
- -
- 613
- 614

# 615 FIGURES & TABLES

#### 616 **Figure 1: Accrual of Long COVID Patients with Persistent Pulmonary Symptoms** 617



<sup>a</sup>Primary SARS-CoV-2 infection was defined as a positive result from a rapid antigen and/or polymerase chain reaction (PCR) test between 03/01/2020 - 08/01/2023

<sup>b</sup>Percent predicted diffusion capacity for carbon monoxide (DLCO) and total lung capacity (TLC) was assessed at the 1st pulmonary Long COVID clinic visit

		Diffusion Imp	aired (≤80% D	LCO)		Diffusion Normal (>80% DLCO)					
	Restriction:	Severe	Moderate	Mild	None	Restriction:	Severe	Moderate	Mild	None	
	TLC:	≤50%	51-70%	71-80%	>80%	TLC:	≤50%	51-70%	71-80%	>80%	
	N=574	n=125	n=247	n=107	n=95	N=355	n=4	n=66	n=99	n=186	
Age <sup>1</sup>	56±13	58±10	56±13	56±15	54±15	48±14	41±7	50±15	50±13	47±14	
Sex					-						
Female	368 (64)	59 (47)	153 (62)	78 (73)	78 (82)	241 (68)	2 (50)	39 (59)	62 (63)	138 (74)	
Male	206 (36)	66 (53)	94 (38)	29 (27)	17 (18)	114 (32)	2 (50)	27 (41)	37 (37)	48 (26)	
Race											
White	340 (59)	65 (52)	131 (53)	70 (65)	74 (78)	250 (70)	0 (0)	30 (45)	71 (72)	149 (80)	
African	190 (33)	47 (38)	101 (41)	25 (23)	17 (18)	71 (20)	3 (75)	27 (41)	23 (23)	18 (10)	
American											
Asian	13 (2)	4 (3)	4 (2)	4 (4)	1 (1)	8 (2)	0 (0)	3 (5)	2 (2)	3 (2)	
Hispanic	9 (2)	3 (2)	3 (1)	3 (3)	0 (0)	5 (1)	0 (0)	1 (2)	0 (0)	4 (2)	
American	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	1 (1)	
Indian											
Multiple	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	1 (1)	
Refused	10 (2)	5 (4)	1 (0)	2 (2)	2 (2)	13 (4)	1 (25)	4 (6)	3 (3)	5 (3)	
Not Reported	10 (2)	1 (1)	5 (2)	3 (3)	1 (1)	6 (2)	0 (0)	1 (2)	0 (0)	5 (3)	
Body-mass Index <sup>1</sup>	33±9	35±10	34±8	32±7	30±8	33±9	46±14	36±9	35±9	32±8	
Pre-COVID											
Comorbidities											
Pulmonary Disease	139 (24)	25 (20)	61 (25)	27 (25)	26 (27)	72 (20)	2 (50)	14 (21)	20 (20)	36 (19)	
Renal Disease	56 (10)	10 (8)	30 (12)	13 (12)	3 (3)	10 (3)	0 (0)	3 (5)	5 (5)	2 (1)	
Diabetes	119 (21)	32 (26)	55 (22)	24 (22)	8 (8)	49 (14)	2 (50)	17 (26)	15 (15)	15 (8)	
Heart Failure/ Hypertension	297 (52)	71 (57)	146 (59)	49 (46)	31 (33)	118 (33)	3 (75)	32 (48)	35 (35)	48 (26)	
Obstructive Sleep Apnea	116 (20)	26 (21)	48 (19)	30 (28)	12 (13)	82 (23)	2 (50)	21 (32)	25 (25)	34 (18)	
Smoking History											
Never smoker	377 (66)	82 (66)	157 (64)	71 (66)	67 (71)	260 (73)	3 (75)	49 (74)	71 (72)	137 (74)	
Former smoker	170 (30)	40 (32)	81 (33)	31 (29)	18 (19)	79 (22)	1 (25)	13 (20)	24 (24)	41 (22)	
Current smoker	27 (5)	3 (2)	9 (4)	5 (5)	10 (11)	16 (5)	0 (0)	4 (6)	4 (4)	8 (4)	
Vaccination Status	104 (18)	22 (18)	51 (21)	18 (17)	13 (14)	80 (23)	1 (25)	13 (20)	21 (21)	45 (24)	

Table 1: Characteristics of Pulmonary Long COVID Patients Stratified by 1<sup>st</sup> Visit Diffusion Capacity and Restriction in the UAB Cohort

	Diffusion Impaired (≤80% DLCO)					Diffusion Normal (>80% DLCO)					
	Restriction:	Severe	Moderate	Mild	None	Restriction:	Severe	Moderate	Mild	None	
	TLC:	≤50%	51-70%	71-80%	>80%	TLC:	≤50%	51-70%	71-80%	>80%	
	N=574	n=125	n=247	n=107	n=95	N=355	n=4	n=66	n=99	n=186	
Primary COVID In	fection				-						
COVID Severity											
(3) No Admission	217 (38)	20 (16)	96 (39)	46 (43)	55 (58)	260 (73)	3 (75)	43 (65)	77 (78)	137 (74)	
(4) Room Air	60 (10)	8 (6)	21 (9)	16 (15)	15 (16)	45 (13)	0 (0)	10 (15)	11 (11)	24 (13)	
(5) Nasal Cannula	139 (24)	29 (23)	69 (28)	24 (22)	17 (18)	32 (9)	0 (0)	8 (12)	5 (5)	19 (10)	
(6) High-Flow Cannula	88 (15)	28 (22)	40 (16)	15 (14)	5 (5)	15 (4)	1 (25)	3 (5)	5 (5)	6 (3)	
(7) Ventilation	70 (12)	40 (32)	21 (9)	6 (6)	3 (3)	3 (1)	0 (0)	2 (3)	1 (1)	0 (0)	
ICU Admission	143 (25)	66 (53)	56 (23)	15 (14)	6 (6)	20 (6)	1 (25)	6 (9)	4 (4)	9 (5)	
Long COVID Visit Primary Symptom											
Dyspnea	454 (79)	111 (89)	196 (79)	78 (73)	69 (73)	271 (76)	3 (75)	52 (79)	74 (75)	142 (76)	
Cough	98 (17)	12 (10)	42 (17)	22 (21)	22 (23)	69 (19)	1 (25)	12 (18)	20 (20)	36 (19)	
Chest Discomfort	22 (4)	2 (2)	9 (4)	7 (7)	4 (4)	15 (4)	0 (0)	2 (3)	5 (5)	8 (4)	
Primary Infection to Long COVID Visit (days) <sup>2</sup>	125 [72-222]	115 [77-170]	123 [67-221]	120 [71-242]	161 [81-256]	148 [80-295]	148 [117-216]	150 [89-403]	182 [81-320]	135 [78-255]	
TLC (%) <sup>1</sup>	65±18	41±7	61±6	75±3	92±11	82±15	49±1	64±5	75±3	93±12	
DLCO (%) <sup>1</sup>	59±16	45±17	61±12	65±14	68±12	95±12	89±6	92±10	92±8	98±14	
CT at 1st Long COVID Clinic Visit	246 (43)	91 (73)	113 (46)	28 (26)	14 (15)	62 (17)	1 (25)	20 (30)	19 (19)	22 (12)	
CT Lung Involvement (0-25 Score) <sup>2</sup>	9 [1-17]	17 [9-21]	7 [1-13]	3 [0-9]	3 [1-7]	0 [0-2]	1 [1-1]	0 [0-2]	0 [0-2]	0 [0-2]	
Time from Long COVID Visit to CT Scan (days) <sup>2</sup>	30 [7-82]	30 [7-70]	28 [7-93]	26 [10-66]	36 [9-94]	21 [7-83]	39 [39-39]	13 [7-55]	24 [10-64]	24 [2-95]	

#### Table 1: Characteristics of Pulmonary Long COVID Patients Stratified by 1<sup>st</sup> Visit Diffusion Capacity and Restriction in the UAB Cohort

Statistics are reported as n, (%) unless otherwise specified by <sup>1</sup>Mean±SD or <sup>2</sup>Median [Q1-Q3]

N=total patients per diffusion capacity stratification group, n=total patients per restriction stratification group

Lung Involvement was assessed with a 0-5 scale (0=no involvement, 1=1-5%, 2=5-25%, 3=25-50%, 4=50-75%, 5≥75%)

Abbreviations: TLC, percent predicted total lung capacity; DLCO, diffusion limitation of carbon monoxide; CT, computerized tomography; WHO, World Health Organization; COVID, coronavirus disease; UAB, University of Alabama at Birmingham

# Figure 2: Diffusion Impaired Restriction is a Key Feature of Persistent Pulmonary Long COVID



**Figure 2 Legend**: (A-B) Results of percent predicted total lung capacity (TLC) and diffusing capacity for carbon monoxide (DLCO) are shown for 3 clinic visits with stratification by restriction severity (color) measured during the 1st visit PFT and presence or absence of diffusion impairment (hashed lines). Boxplots represent the median black center line; 25th and 75th percentile box boundaries) for each PFT measured, with number of patients (N) reported below each group. Normal TLC and DLCO are denoted by the grey color on the plot at 80%. (C) Alluvial diagram displays patient PFT trajectories over 3-consecutive visits (N=100 total) with relative improvement or decline as measured by TLC (color) and DLCO (hashed lines). Labelling of alluvial diagram axes groups with <5 patients was omitted for visual clarity.

#### Table 2: Risk Factors for Pulmonary Long COVID with Diffusion Impaired Restriction

		Diffusion Impaired	Diffusion Impaired	Diffusion Impaired
	Patients	Restriction <sup>2</sup>	Restriction	Restriction
	Total N	N (% of Total)	Unadjusted OR [95% CI] <sup>1</sup>	Adjusted OR [95% CI] <sup>1</sup>
Advanced Age				
<65 years	743	280 (38)		
≥65 years	186	92 (49)	1.63 [1.23-2.23]	1.22 [0.81-1.88]
Sex				
Female	609	212 (35)	<u> </u>	_
Male	320	160 (50)	1.88 [1.43-2.48]	1.44 [1.03-1.98]
Elevated BMI				
<30	376	138 (37)	<u> </u>	
≥30	553	234 (42)	1.28 [0.97-1.66]	1.27 [0.91-1.77]
Pulmonary Disease				
No	718	286 (40)	<u> </u>	
Yes	211	86 (41)	1.04 [0.76-1.41]	0.95 [0.67-1.36]
Renal Disease				
No	863	332 (38)	_	_
Yes	66	40 (61)	2.48 [1.47-4.15]	1.03 [0.57-1.99]
Diabetes				
No	761	285 (37)	<u> </u>	—
Yes	168	87 (52)	1.82 [1.30-2.51]	1.20 [0.79-1.78]
Heart Failure or Hypertension				
No	514	155 (30)		·
Yes	415	217 (52)	2.54 [1.98-3.32]	2.09 [1.46-2.99]
Obstructive Sleep Apnea				
No	731	298 (41)		·
Yes	198	74 (37)	0.88 [0.63-1.17]	0.51 [0.32-0.72]
Smoking History				
Never smoker	637	239 (38)		·
Current or Former Smoker	292	133 (46)	1.39 [1.03-1.86]	1.25 [0.89-1.74]
Vaccination Status				
No	745	299 (40)		·
Yes	184	73 (40)	0.99 [0.72-1.39]	1.34 [0.89-1.99]
Months from Primary Infection				
to Long COVID Clinic Visit				
1-3 Months	306	132 (43)		
3-6 Months	292	139 (48)	1.19 [0.88-1.64]	0.96 [0.67-1.39]
6-12 Months	197	59 (30)	0.56 [0.38-0.81]	0.70 [0.44-1.10]
>12 Months	134	42 (31)	0.61 [0.40-0.89]	0.64 [0.37-1.09]
ICU Admission				
No	766	250 (33)		·
Yes	163	122 (75)	6.15 [4.24-9.36]	1.48 [0.71-3.27]
COVID Severity (WHO Score)				
(3) No Admission	477	116 (24)		·
(4) Room Air	105	29 (28)	1.20 [0.71-1.93]	1.03 [0.57-1.73]
(5) Nasal Cannula	171	98 (57)	4.21 [2.90-6.07]	4.00 [2.61-6.33]
(6) High-Flow Cannula	103	68 (66)	6.10 [3.92-9.82]	3.86 [1.73-8.09]
(7) Ventilation	73	61 (84)	16.0 [8.87-34.4]	10.9 [4.09-28.6]

<sup>1</sup>Unadjusted odds ratio (OR) and adjusted odds ratio (aOR), 95% confidence interval (n=1000 bootstraps)

<sup>2</sup>Diffusion impaired restriction is defined by a DLCO ≤80% and a TLC ≤70% measured by PFT at the 1<sup>st</sup> Long COVID clinic visit

# Figure 3: CT Image Findings in Pulmonary Long COVID with Diffusion Impaired Restriction



**Figure 3 Legend**: (A-D) Representative CT images of pulmonary Long COVID patients with diffusion impairment (DLCO  $\leq$ 80%) with severe (TLC  $\leq$ 50%), moderate (TLC 51-70%), mild (TLC 71-80%), and no restriction (TLC >80%) assessed at the 1st Long COVID clinic visit. Corresponding barcharts of CT pathology (%, N=patients) are displayed for each group. (Note: architectural distortion, traction bronchiectasis and honeycombing are termed 'Other Fibrosis').